Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
- Conditions
- HealthyDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Drug: LY4057996 SCDrug: Placebo SCDrug: Degludec SCDrug: LY4057996 IVDrug: Placebo IVDrug: Lispro SCDrug: Degludec IVDrug: Pre-study basal insulin SC
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 132
- Registration Number
- NCT06945406
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Conditions
- Crohn's DiseaseObesity or Overweight
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 290
- Registration Number
- NCT06937099
- Locations
- 🇺🇸
California Medical Research Associates, Northridge, California, United States
🇺🇸Precision Clinical Research, Sunrise, Florida, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Conditions
- Ulcerative ColitisObesity or Overweight
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 350
- Registration Number
- NCT06937086
- Locations
- 🇺🇸
California Medical Research Associates, Northridge, California, United States
🇺🇸Precision Clinical Research, Sunrise, Florida, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 88
- Registration Number
- NCT06937411
- Locations
- 🇬🇧
The Medicines Evaluation Unit Ltd., Manchester, United Kingdom
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
- Conditions
- Atopic Hand and Foot Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 206
- Registration Number
- NCT06921759
- Locations
- 🇯🇵
Pansy Skin Clinic, Saitama, Japan
🇰🇷The Catholic University of Korea, Incheon St. Mary's Hospital, Bupyeong-gu, Incheon-gwangyeoksi [Incheon], Korea, Republic of
🇰🇷Korea University Ansan Hospital, Ansan-si, Kyǒnggi-do, Korea, Republic of
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT06916091
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
- Conditions
- OverweightObesity
- Interventions
- Drug: Eloralintide and Tirzepatide
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 188
- Registration Number
- NCT06916065
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT06916143
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT06916078
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation at Texas Liver Institute, San Antonio, Texas, United States
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
- Conditions
- Type 1 DiabetesObesityOverweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 905
- Registration Number
- NCT06914895
- Locations
- 🇯🇵
Kumamoto Central Hospital - Kumamoto, Kumamoto, Japan
🇺🇸Sansum Diabetes Research Institute, Goleta, California, United States
🇺🇸Care Access - Santa Clarita, Santa Clarita, California, United States